SynVaccine has developed a CAD/CAM platform for designing and fabricating designer viruses for biotechnology. The company utilizes a multidisciplinary approach combining technologies, such as synthetic biology, virology, bio-informatics, engineering, and robotics, to make viruses that can be used to develop new vaccines.

SynVaccine's technology enables the design and fabrication of viral genomes using a safety-focused design approach. The resulting viruses have the potential to overcome the limitations of those found in nature or developed through traditional technologies.

SynVaccine was founded as part of Rad BioMed, an Israel-based evergreen family fund that invests in early-stage biomedical start-ups, and on the basis of commercialized research from Tel Aviv University and Weizmann Institute of Science led by Professor Tamir Tuller.